Claris Law Legal Blogging Community

Name:

E-mail:

Phone Number:

Zip Code:

Your Question:

Editor: M. Brandon Smith
Profession: Attorney at Law

Category: Mesothelioma News

The FDA's stamp of approval is being sought for a new drug, ONCONASE, that is designed to treat patients with unresectable malignant mesothelioma (UMM).

According to NJBiz.com:

Alfacell Corporation (Nasdaq: ACEL), a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonuclease therapeutics for cancer, today announced it has filed an application with the U.S. Food and Drug Administration (FDA) to obtain orphan designation for its lead drug candidate ONCONASE® (ranpirnase) for the treatment of patients with unresectable malignant mesothelioma (UMM).

Although the long term effects of ONCONASE (also know as P-30 protein) are still being studied, the drug's approval could be good news for those who suffer from this type of mesothelioma. In its earlier studies , ONCONASE (ranpirnase), has been shown to increase the median survival rates in patients who take the drug as prescribed.

If approved, the drug manufacturer will have the exclusive rights to market this drug for the next seven years.